Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08SKH
|
|||
| Former ID |
DAP000996
|
|||
| Drug Name |
Methoxsalen
|
|||
| Synonyms |
Ammodin; Ammoidin; Deltasoralen; Dermox; Geroxalen; Meladinin; Meladinina; Meladinine; Meladoxen; Meloxine; Methoxalen; Methoxaten; Oxoralen; Oxsoralen; Oxypsoralen; Puvalen; Puvamet; Ultramop; Uvadex; XANTHOTOXIN; Xanthotoxine; Zanthotoxin; Boehringer Ingelheim Brand of Methoxsalen; Canderm Brand of Methoxsalen; Chinoin Brand of Methoxsalen; DB Brand of Methoxsalen; Delta Brand of Methoxsalen; Dermatech Brand of Methoxsalen; Galderma Brand of Methoxsalen; Methoxa Dome; Methoxsalen Canderm Brand; Methoxsalen Chinoin Brand; Methoxsalen Delta Brand; Methoxsalen Dermatech Brand; Methoxsalen plus ultraviolet radiation; Mex America Brand of Methoxsalen; Oxsoralen Ul tra; Oxsoralen Ultra; Oxsoralen lotion; Sanofi Synthelabo Brand of Methoxsalen; Ultra Mop; Ultramop Lotion; ICN Brand 1 of Methoxsalen; ICN Brand 2 of Methoxsalen; ICN Brand 3 of Methoxsalen; X0009; An 8-methoxyfurocoumarin; Meladinin (VAN); Methoxa-Dome; Methoxsalen Mex-America Brand; Methoxsalen Sanofi-Synthelabo Brand; Methoxsalen [BAN:JAN]; Methoxsalen with ultra-violet A theraphy; Mex-America Brand of Methoxsalen; New-Meladinin; O-methylxanthotoxol; OXSORALEN (TN); Oxsoralen (TN); Oxsoralen-ultra; Proralone-mop; Psoralen-mop; Psoralon-MOP; Sanofi-Synthelabo Brand of Methoxsalen; Methoxsalen (JP15/USP); Methoxy-8-psoralen; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; 7-Furocoumarin; 8 Methoxypsoralen; 8-METHOXYPSORALEN + UVA (SEE ALSO C55903); 8-MOP; 8-Methoxy; 8-Methoxy(furano-3'.2':6.7-coumarin); 8-Methoxy-(furano-3'.2':6.7-coumarin); 8-Methoxy-2',3',6,7-furocoumarin; 8-Methoxy-4',5',6,7-furocoumarin; 8-Methoxy-4',5':6,7-furocoumarin; 8-Methoxy-[furano-3'.2':6.7-coumarin]; 8-Methoxyfuranocoumarin; 8-Methoxypsoralen; 8-Methoxypsoralen with ultraviolet A therapy; 8-Methoxypsoralene; 8-methoxyfuranocoumarins; 8-methoxyfurocoumarins; 8MO; 8MOP; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; 9-Methoxyfuro(3,2-g)chromen-7-one; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; 9-Methoxypsoralen; 9-metho xy-7H-furo(3,2-g)benzopyran-7-one; 9-methoxyfuro[3,2-g]chromen-7-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cutaneous T-cell lymphoma [ICD-11: 2B01; ICD-10: C84.0] | Approved | [1], [2] | |
| Psoriasis vulgaris [ICD-11: EA90] | Approved | [1], [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H8O4
|
|||
| Canonical SMILES |
COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2
|
|||
| InChI |
1S/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3
|
|||
| InChIKey |
QXKHYNVANLEOEG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 298-81-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
4978, 99459, 597343, 2465957, 3139055, 3496877, 4255217, 7666801, 7847207, 7884115, 7885536, 7979935, 8025195, 8138256, 8145159, 8149421, 8152581, 10321621, 10517620, 11112313, 11335938, 11361177, 11363917, 11366479, 11369041, 11371597, 11373682, 11377203, 11408476, 11462149, 11466507, 11467627, 11484740, 11486293, 11488868, 11490315, 11491867, 11494837, 11534753, 14822550, 17389831, 24896845, 26611816, 26679584, 26747188, 26747189, 26752292, 29204678, 29223222, 46506275
|
|||
| ChEBI ID |
CHEBI:18358
|
|||
| ADReCS Drug ID | BADD_D01420 | |||
| SuperDrug ATC ID |
D05AD02; D05BA02
|
|||
| SuperDrug CAS ID |
cas=000298817
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides caccae ATCC 43185
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Bacteroides caccae ATCC 43185 (log2FC = -0.506; p = 0.019). | |||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -1.011; p = 0.004). | |||
|
Studied Microbe: Bacteroides eggerthii DSM20697
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Bacteroides eggerthii DSM20697 (log2FC = -0.458; p = 0.036). | |||
|
Studied Microbe: Bacteroides finegoldii DSM17565
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Bacteroides finegoldii DSM17565 (log2FC = -1.089; p = 0.038). | |||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -0.93; p = 0.016). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.774; p = 0.025). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.588; p = 0.02). | |||
|
Studied Microbe: Bacteroides fragilis NCTC 9343
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Bacteroides fragilis NCTC 9343 (log2FC = -0.711; p = 0.045). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -0.47; p = 0.037). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -0.918; p = 0.015). | |||
|
Studied Microbe: Bacteroides xylanisolvens DSM18836
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Bacteroides xylanisolvens DSM18836 (log2FC = -0.709; p = 0.006). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Odoribacter splanchnicus (log2FC = -0.565; p = 0.05). | |||
|
Studied Microbe: Parabacteroides distasonis ATCC 8503
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Parabacteroides distasonis ATCC 8503 (log2FC = -0.483; p = 0.039). | |||
|
Studied Microbe: Parabacteroides johnsonii DSM 18315
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Parabacteroides johnsonii DSM 18315 (log2FC = -0.492; p = 0.026). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Clostridium ramosum DSM 1402
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Clostridium ramosum DSM 1402 (log2FC = -10.146; p = 0.01). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia hansenii DSM20583
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Blautia hansenii DSM20583 (log2FC = -0.664; p = 0.009). | |||
|
Studied Microbe: Clostridium sporogenes ATCC 15579
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Methoxsalen can be metabolized by Clostridium sporogenes ATCC 15579 (log2FC = -0.613; p = 0.013). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytochrome P450 2A6 (CYP2A6) | Target Info | Binder | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009048. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Mutagenicity and carcinogenicity of methoxsalen plus UV-A. Arch Dermatol. 1984 May;120(5):662-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.